Overview Financials News + Filings Key Docs Charts Transactions Ownership Insiders
All All (ex-4s) 10-K 10-Q 8-K 3,4,5 Proxy Prospectus Other
Tags CC transcript Credit agrmnt [a] Appointed director Inv. presentation Quarterly results Acq. announced Director departure
|
Bausch Health Companies Inc. (BHC)
|
Create: Alert |
All | News | Filings
Date Filed | Type | Description |
02/08/2021 |
GN
| Clearside Biomedical Featured in Multiple Data Presentations at the 44th Virtual Annual Macula Society Meeting |
11/12/2020 |
GN
| Sol-Gel Technologies Reports Third Quarter 2020 Financial Results and Corporate Update |
09/23/2020 |
GN
| Clearside Biomedical Announces Clinical Data Presentations at The Retina Society 2020 and Publication of XIPERE™ Data in Diabetic Macular Edema in Ophthalmology Retina |
09/03/2020 |
GN
| Sol-Gel Technologies Collaboration Partner Filed First-to-File Paragraph IV Certification for Duobrii® |
06/29/2020 |
GN
| Sol-Gel Technologies Announces Agreements with Perrigo Company for Three New Generic Product Candidates |
08/20/2018 |
GN
| RedHill Biopharma Receives Allowance for New U.S. Patent Covering RHB-106, an Encapsulated Bowel Preparation |
05/07/2018 |
GN
| Safirstein Metcalf LLP and HGT Law Remind Investors That a Shareholder Opt-out Lawsuit was Filed on Behalf of Retail Investors and Invite Investors to Contact the Firms - VRX |
04/09/2018 |
GN
| New Research Coverage Highlights SINOPEC Shangai Petrochemical, Aurinia Pharmaceuticals, Valeant Pharmaceuticals International, NTT DOCOMO, Southern Missouri, and KNOT Offshore Partners LP — Consolidated Revenues, Company Growth, and Expectations for 2018 |
04/06/2018 |
GN
| EyeGate Completes Enrollment and Receives Milestone Payment for Confirmatory Phase 3 Clinical Study of EGP-437 in Anterior Uveitis |
03/14/2018 |
GN
| Report: Developing Opportunities within NRG Yield, Stitch Fix, Encana, Valeant Pharmaceuticals International, Orbotech, and CoreCivic, Inc. — Future Expectations, Projections Moving into 2018 |
01/29/2018 |
GN
| Safirstein Metcalf LLP and HGT Law Commence a Securities Fraud Action Against Valeant Pharmaceuticals and its Senior Officers on Behalf of Retail Investors - VRX |
|
|